Wednesday, August 20, 2025
Noble Capital Markets Initiate
STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM
Tuesday, August 19, 2025
Greenwich LifeSciences Announc
STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM
Saturday, August 16, 2025
Owning 53% in Greenwich LifeSc
Key Insights Significant insider control over Greenwich LifeSciences implies vested interests in company growth The top...
Wednesday, August 13, 2025
Greenwich LifeSciences Announc
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM
Monday, August 11, 2025
Greenwich LifeSciences Provide
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an im
Sunday, June 29, 2025
Certain Common Stock of Greenw
Certain Common Stock of Greenwich LifeSciences, Inc. are subject to a Lock-Up Agreement Ending on 30-JUN-2025. These Common Stock will be under lockup for 1740 days starting from 24-SEP-2020 to...
Friday, June 27, 2025
Greenwich LifeSciences Intervi
ORLANDO, FLORIDA / ACCESS Newswire / June 27, 2025 / RedChip Companies will air an interview with Greenwich LifeSciences, Inc. (Nasdaq:GLSI) on the RedChip Small Stocks, Big Money™ show, a sponsored p
Friday, May 9, 2025
Greenwich LifeSciences: What T
Greenwich LifeSciences showed initial HER2 data, yet faces funding issues and competitive pressure in a fast-moving field. See why GLSI stock is a sell.
Thursday, April 3, 2025
Greenwich LifeSciences Provide
STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA
Wednesday, April 2, 2025
Greenwich LifeSciences Announc
STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA
Thursday, March 27, 2025
Greenwich LifeSciences Extends
STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA
Monday, March 17, 2025
Greenwich LifeSciences Provide
STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLA
Wednesday, March 5, 2025
55% of Greenwich LifeSciences,
Key Insights Significant insider control over Greenwich LifeSciences implies vested interests in company growth 53% of...
Monday, February 10, 2025
Greenwich LifeSciences Provide
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM
Thursday, February 6, 2025
Greenwich LifeSciences: Long T
Greenwich LifeSciences, Inc. has a short cash runway, unclear market potential, and a high risk of trial failure. Learn more about GLSI stock here.
Thursday, January 30, 2025
EMA approves addition of sites
The approved expansion will allow the activation of nearly 110-115 sites throughout Europe.
Wednesday, January 29, 2025
Greenwich LifeSciences Approve
STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM
Monday, January 27, 2025
Greenwich LifeSciences Announc
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM
Thursday, January 23, 2025
Bullish Greenwich LifeSciences
In the last year, multiple insiders have substantially increased their holdings of Greenwich LifeSciences, Inc...
Thursday, January 23, 2025
Greenwich LifeSciences Announc
STAFFORD, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM
Wednesday, January 22, 2025
Greenwich LifeSciences Provide
STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM
Friday, January 17, 2025
Glancy Prongay & Murray LLP An
Glancy Prongay & Murray LLP announces its investigation of Greenwich LifeSciences, Inc. concerning the Company and its directors’ and officers’ possible violations of state laws.If you own...
Tuesday, January 14, 2025
Greenwich LifeSciences Announc
STAFFORD, Texas, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM
Monday, January 13, 2025
Greenwich LifeSciences Partner
STAFFORD, Texas, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM
Monday, January 13, 2025
Greenwich LifeSciences : State
Ownership Submission FORM 4 Check this box if no longer...
Tuesday, November 26, 2024
Greenwich LifeSciences Partner
STAFFORD, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAM
Monday, November 18, 2024
Greenwich LifeSciences Provide
STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an im
Monday, October 7, 2024
Greenwich LifeSciences files f
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Monday, October 7, 2024
Greenwich LifeSciences files $
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Monday, September 30, 2024
Insider Buying: CEO and CFO Sn
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Thursday, September 12, 2024
Greenwich LifeSciences, Inc. (
Key Insights Insiders appear to have a vested interest in Greenwich LifeSciences' growth, as seen by their sizeable...